A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling
Unlike its efficacy in NTRK-fusion positive cancers, larotrectinib did not demonstrate a signal of efficacy among tumors with NTRK overexpression.
Authors
- Michael D. Brown (ORCID: https://orcid.org/0000-0002-0370-8077)
- Hao‐Wen Sim (ORCID: https://orcid.org/0000-0002-2530-0523)
- Margaret E. McGrath
- Frank Lin (ORCID: https://orcid.org/0000-0001-9250-6874)
- John P. Grady (ORCID: https://orcid.org/0000-0001-9667-3872)
- Subotheni Thavaneswaran (ORCID: https://orcid.org/0000-0002-8946-6709)
- David M. Thomas (ORCID: https://orcid.org/0000-0002-2527-5428)
- Robert John Simes (ORCID: https://orcid.org/0000-0002-3740-7563)
- Jayesh Desai (ORCID: https://orcid.org/0000-0003-4246-9344)
- Maya Kansara (ORCID: https://orcid.org/0000-0003-1908-3574)
- Michail Charakidis (ORCID: https://orcid.org/0000-0003-0791-203X)
- Min Huang (ORCID: https://orcid.org/0000-0002-9278-6594)
- David Espinoza
Institutions
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- Garvan Institute of Medical Research (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Princess Alexandra Hospital (AU)
- Charles Darwin University (AU)
- St Vincent's Hospital Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- Cancer Clinic (US)
- Royal Darwin Hospital (AU)
- Princess Alexandra Hospital (GB)
- The Kinghorn Cancer Centre (AU)
- National Health and Medical Research Council (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1093/oncolo/oyae339
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.44